Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T‐cell therapy can be identified before cell administration

Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T‐cell therapy can be identified before cell administration

Abstract Aim The aim of this study was to analyse the outcomes of patients with large B‐cell lymphoma (LBCL) treated with chimeric antigen receptor T‐cell therapy (CAR‐Tx), with a focus on outcomes after CAR T‐cell failure, and to define the risk factors for rapid progression and further treatment....

Full description

Saved in:
Bibliographic Details
Main Authors: Alice Sýkorová, František Folber, Kamila Polgárová, Heidi Móciková, Juraj Ďuraš, Kateřina Steinerová, Aleš Obr, Adriana Heindorfer, Miriam Ladická, Ľubica Lukáčová, Erika Čellárová, Ivana Plameňová, David Belada, Andrea Janíková, Marek Trněný, Tereza Jančárková, Vít Procházka, Andrej Vranovský, Margaréta Králiková, Jan Vydra, Lukáš Smolej, Ľuboš Drgoňa, Martin Sedmina, Eva Čermáková, Robert Pytlík
Format: Article
Language:English
Published: Wiley 2024-09-01
Series:Cancer Medicine
Subjects:
CAR T‐cell failure
outcomes of patients after CAR T‐cell therapy failure
relapsed/refractory large B‐cell lymphoma
risk factors for CAR T‐cell therapy failure
Online Access:https://doi.org/10.1002/cam4.70138
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.70138

Similar Items